Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma [PDF]
G d’Ancona+9 more
openalex +1 more source
Peak nasal inspiratory flow assessment of polyp size and response from SYNAPSE
Background: In the phase III SYNAPSE study, mepolizumab plus standard of care reduced total endoscopic nasal polyp score (NPS) versus that with placebo in patients with chronic rhinosinusitis with nasal polyps.
Amber U. Luong, MD, PhD+8 more
doaj
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation [PDF]
Diego Bagnasco+8 more
openalex +1 more source
Benralizumab after sub‐optimal response to mepolizumab in severe eosinophilic asthma [PDF]
Joanne Kavanagh+10 more
openalex +1 more source
Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome
Florence Roufosse+10 more
openalex +1 more source
Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma [PDF]
Frank C. Albers+7 more
openalex +1 more source
Background The advent of biologics has resulted in major progress in the treatment of severe T2 high asthmatics. There are currently several classes of biologics approved for severe asthma including anti-immunoglobulin E, anti-interleukin-5/interleukin ...
M. Sabbe+3 more
doaj +1 more source
Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study [PDF]
Giovanna Elisiana Carpagnano+10 more
openalex +1 more source
Allergic bronchopulmonary aspergillosis complicated by eosinophilic chronic rhinosinusitis successfully treated with mepolizumab [PDF]
Nobuhiro Matsumoto+5 more
openalex +1 more source
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study [PDF]
P. Jane McDowell+42 more
openalex +1 more source